Journal Information
Vol. 41. Issue 7.
Pages 380-384 (July 2005)
Share
Share
Download PDF
More article options
Vol. 41. Issue 7.
Pages 380-384 (July 2005)
Original Articles
Full text access
Lung Function Testing in Patients With Pulmonary Arterial Hypertension
Visits
5576
P. Martín Escribanoa,
Corresponding author
pmartin.hdoc@salud.madrid.org

Correspondence: Dr. P. Martín Escribano. Servicio de Neumología. Hospital Universitario 12 de Octubre. Avda. Córdoba, s/n. 28041 Madrid. España
, M.A. Gómez Sánchezb, M.J. Díaz de Atauria, J. Palomera Fradea, I. Martín Garcíac
a Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, Spain
b Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
c Unidad de Epidemiología Clínica, Hospital Universitario 12 de Octubre, Madrid, Spain
This item has received
Article information
Objective

The main objective was to describe the results of lung function testing in a series of 120 patients with pulmonary arterial hypertension, and the secondary objective was to compare these findings with hemodynamic variables.

Patients and methods

This was a descriptive study of lung function in 120 patients with stable pulmonary arterial hypertension (Evian/Venice groups 1 and 4) studied until January 2002 in the Pulmonary Hypertension and Lung Transplant Working Group attached to the Cardiology Department of the Hospital Universtario 12 de Octubre in Madrid, Spain. Data were collected retrospectively for the first 47 patients (1981 to 1995) and prospectively thereafter for the remaining 73 patients. The diagnosis was idiopathic arterial hypertension or hypertension associated with collagen disease, chronic pulmonary embolism, cardiac shunt, or toxic oil syndrome (30 cases).

Results

In the group as a whole, forced vital capacity, forced expiratory volume in 1 second, and total lung capacity were normal; mean (SD) values revealed low carbon dioxide diffusing capacity (67.6% [23.2%]), and moderate hypoxemia (65.8 [15.4] mm Hg). No significant associations were observed between lung function and hemodynamic parameters. Mean age in the toxic oil syndrome group was lower (33.7 [11.4] years), and these patients had higher mean scores on the New York Heart Association scale (3.3 [0.5]) and for pulmonary vascular resistance (20.3 [8.1] kPa·L-1·s).

Conclusions

Lung function was studied in a series of 120 patients with pulmonary arterial hypertension (Evian/ Venice groups 1 and 4), 30 of whom had toxic oil syndrome. No significant associations were found between lung function and hemodynamic parameters.

Key Words:
Lung function tests
Pulmonary hypertension
physiopathology, diagnosis
Objetivo

El objetivo principal es la descripción de los hallazgos funcionales respiratorios en una serie de 120 pacientes con hipertensión arterial pulmonar (HAP), y el objetivo secundario es su comparación con los datos hemodinámicos.

Pacientes y métodos

Estudio descriptivo de la función pulmonar de los 120 casos con HAP estable, de los grupos 1 y 4 de Evian/Venecia, estudiados hasta enero de 2002 en el grupo de trabajo de Hipertensión Pulmonar y Trasplante de Pulmón del Servicio de Cardiología del Hospital Universitario 12 de Octubre de Madrid. Los datos de 47 pacientes se recogieron retrospectivamente desde 1981 a 1995, y de forma prospectiva en los 73 restantes. Se incluyeron casos de hipertensión arterial idiopática y de la asociada a colagenosis, tromboembolia pulmonar crónica, shunt cardíaco y, en 30 casos, a síndrome de aceite tóxico (SAT).

Resultados

En el conjunto del grupo la capacidad vital, el volumen espiratorio forzado en el primer segundo y la capacidad pulmonar total fueron normales; los valores medios mostraron un factor de transferencia bajo (media ± desvia-ción estándar: 67,6 ± 23,2), e hipoxemia moderada (65,8 ± 15,4 mmHg). No se observaron asociaciones significativas entre los parámetros funcionales pulmonares y los hemodinámicos. El grupo con SAT tenía la edad más baja (33,7 ± 11,4 años), junto a los valores medios más altos en la escala de la New York Heart Association (3,3 ± 0,5) y de resistencias vasculares pulmonares (20,3 ± 8,1 kPa·l-1·s).

Conclusiones

En este trabajo se estudia la función pulmonar en una serie de 120 pacientes con HAP, de los grupos 1 y 4 de Evian/Venecia, entre los que se incluyó a 30 casos con SAT. No se han encontrado asociaciones significativas entre los valores funcionales respiratorios y los hemodinámicos.

Palabras clave:
Pruebas de función pulmonar
Hipertensión pulmonar
Diagnóstico de la hipertensión
fisiopatología, pulmonar
Full text is only aviable in PDF
REFERENCES
[1]
World Symposium on Pulmonary Hypertension 1998 Evian. Geneva: World Health Organization.
[2]
G Simonneau, N Galie, LJ Rubin, D Langleben, W Seeger, G Domenighetti, et al.
Clinical classification of pulmonary hypertension.
J Am Coll Cardiol, 43 (2004), pp. S5-S12
[3]
Toxic Epidemic Syndrome Study Group.
Toxic epidemic syndrome. Spain 1981.
Lancet, ii (1982), pp. 697-702
[4]
Report Working Party “Standardization of Lung Function Tests.”.
Official Statement of the European Respiratory Society.
Eur Respir J, 6 (1993), pp. 5-52
[5]
P Martín Escribano.
Respiratory functional studies during the neuromyopathic phase and last functional studies.
Eur J Respir Dis, 64 (1983), pp. 423
[6]
P Martín Escribano, JM Fernández Sánchez-Alarcos, MJ Domínguez Lozano, MJ Díaz de Atauri, C Barbosa Ayúcar, JA Cantalapiedra, et al.
Exploration fonctionelle aux differentes stades du syndrome du a l'huile toxique.
Bull Eur Physiopathol Respir, 20 (1984), pp. 307-312
[7]
MJ Díaz de Atauri, MM Ramis Pedromingo, P Martín Escribano.
Disnea en pacientes afectos por ingesta de aceite tóxico; ¿origen psicosomático o secundario a alteración funcional pulmonar?.
Med Clin (Barc), 87 (1986), pp. 523
[8]
MA Gómez Sánchez, MJ Mestre de Juan, C Gómez Pajuelo, MJ Díaz de Atauri, FJ Martínez Tello.
Pulmonary hypertension due to toxic oil syndrome: a clinicopathologic study.
Chest, 95 (1989), pp. 325-331
[9]
MA Gómez Sánchez, MJ Díaz de Atauri, M Alonso Gutiérrez, P Martín Escribano, C Sáenz de la Calzada, C Gómez Pajuelo, et al.
Dynamic pulmonary arterial hypertension: a new form of pulmonary hypertension in patients with impaired pulmonary diffusing capacity due to toxic oil syndrome.
Cor Vasa, 32 (1990), pp. 211-217
[10]
P Martín Escribano, MJ Díaz de Atauri.
Síndrome tóxico y asma.
Arch Bronconeumol, 26 (1990), pp. 377-378
[11]
P Martín Escribano, MJ Díaz de Atauri, MA Gómez Sánchez.
Persistence of respiratory abnormalities four years after the onset of toxic oil syndrome.
Chest, 100 (1991), pp. 336-339
[12]
MA Gómez Sánchez, C Sáenz de la Calzada, C Gómez Pajuelo, FJ Martínez Tello, MJ Mestre de Juan, TN James.
Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome.
J Am Coll Cardiol, 18 (1991), pp. 1539-1545
[13]
MJ Díaz de Atauri.
Afectación pulmonar en el síndrome del aceite tóxico: estudio evolutivo de nueve años de enfermedad [doctoral thesis], Universidad Autónomade Madrid, (1992),
[14]
S Rich, DR Dantzker, SM Ayres, EH Bergofsky, BH Brundage, KM Detre, et al.
Primary pulmonary hypertension.
Ann Inter Med, 107 (1987), pp. 216-223
[15]
LJ Rubin.
Primary pulmonary hypertension.
N Engl J Med, 336 (1997), pp. 111-117
[16]
PF Fedullo, WR Auger, KM Kerr, LJ Rubin.
Chronic thromboembolic pulmonary hypertension.
N Engl J Med, 345 (2001), pp. 1465-1472
[17]
J Loscalzo.
Genetic clues to the cause of primary pulmonary hypertension.
N Engl J Med, 345 (2001), pp. 367-371
[18]
H Olschewski, F Rose, E Grunig, HA Ghofrani, D Walmarth, R Schultz, et al.
Cellular pathophysiology and therapy of pulmonary hypertension.
J Lab Clin Med, 138 (2001), pp. 367-377
[19]
RD Machado, MW Pauciulo, JR Thomson, KB Lane, NV Morgan, L Wheelar, et al.
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.
Am J Hum Genet, 68 (2001), pp. 92-102
[20]
D Theegarten, O Anhenn, S Aretz, M Maass, G Mogilevski.
Detection of Chlamydia pneumoniae in unexplained pulmonary hypertension.
Eur Respir J, 19 (2002), pp. 192-194
[21]
AD Lee, KR Shroyer, NE Markham, CD Cool, NF Voelkel, RM Tuder.
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.
J Clin Invest, 101 (1998), pp. 927-934
[22]
JSR Gibbs.
British Cardiac Society. Recommendations on the management of pulmonary hypertension in clinical practice.
Thorax, 86 (2001), pp. 1-13
[23]
JV Conte, MJ Borja, CB Patel, SC Yang, RM Jhaveri, JB Orens.
Lung transplantation for primary and secondary pulmonary hypertension.
Ann Thorac Surg, 72 (2001), pp. 1673-1679
[24]
R Kessler, A Chaouat, E Weitzenblum, M Oswald, M Ehrhart, M Apprill, et al.
Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences.
Eur Respir J, 9 (1996), pp. 787-794
[25]
R Naeije, JA Barberá.
Pulmonary hypertension associated with COPD.
Crit Care, 5 (2001), pp. 286-289
[26]
CM Burke, AR Glandville, AJ Morris, D Rubin, JA Harvey, J Theodore, et al.
Pulmonary function in advanced pulmonary hypertension.
Thorax, 42 (1987), pp. 131-135
[27]
AM Romano, S Tomaselli, G Gualtieri, MC Zoia, F Fanfulla, L Berrayah, et al.
Respiratory function in precapillary pulmonary hypertension.
Monaldi Arch Chest Dis, 48 (1993), pp. 201-204
[28]
AB Waxman.
Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure.
Clin Chest Med, 22 (2001), pp. 751-758
[29]
LH Steenhuis, HJM Groen, GH Koeter, TW van den Mark.
Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension.
Eur Respir J, 16 (2000), pp. 276-281
[30]
RJ Bernstein, RL Ford, JL Clausen, KM Moser.
Membrane diffusion and capillary blood volume in chronic thromboembolic pulmonary hypertension.
Chest, 110 (1996), pp. 1430-1436
[31]
LJ Rubin.
Primary pulmonary hypertension. ACCP Consensus Statement.
Chest, 104 (1993), pp. 236-250
[32]
XG Sun, JE Hansen, RJ Oudiz, K Wasserman.
Exercise pathophysiology in patients with primary pulmonary hypertension.
Circulation, 104 (2001), pp. 429-435
[33]
RG Ungerer, DP Tashkin, D Furst, PJ Clements, H Gong Jr, M Bein, et al.
Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.
Am J Med, 75 (1983), pp. 65-74
[34]
G Paciocco, FJ Martínez, E Bossone, E Pielsticker, B Guillespie, M Rubenfire.
Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.
Eur Respir J, 17 (2001), pp. 647-652
[35]
CJ McMahon, J Kadkin, MR Nihill.
Rapid regression of primary pulmonary hypertension.
Heart, 86 (2001), pp. E1

This work was sponsored by RTIC CO3/011

Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?